Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Abstracts From the 2020 IDEOM Meeting","authors":"","doi":"10.1177/24755303211043842","DOIUrl":"https://doi.org/10.1177/24755303211043842","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"223 - 226"},"PeriodicalIF":0.0,"publicationDate":"2021-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41436076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series","authors":"E. Song, A. Wong","doi":"10.1177/24755303211037308","DOIUrl":"https://doi.org/10.1177/24755303211037308","url":null,"abstract":"Background: Biologic switching is not uncommon in the treatment of psoriasis and is most often due to inadequate response of adverse events. Staying within or switching out of the class is still based on expert opinion but there are published data on intra-class switching with TNF-alpha and IL-17 inhibitors. Less is known about the IL-23 inhibitors because of their limited time in the market. We would like to present our experience with inadequate responders to tildrakizumab, a selective IL23 inhibitor, who were switched to an alternative IL-23 inhibitor. Case Description: This is a case series of 6 patients at a single institution considered inadequate responders to tildrakizumab, which included primary failures, secondary failures, and intermediate responders, who were subsequently switched to another IL-23 inhibitor. Conclusion: All 6 patients who were inadequate responders to tildrakizumab showed significant improvement after switching to another IL-23 inhibitor, with 5/6 reaching IGA 0/1 after 16 weeks of treatment.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"166 - 169"},"PeriodicalIF":0.0,"publicationDate":"2021-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211037308","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47552761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab","authors":"Kayla H. Taylor, S. Feldman","doi":"10.1177/24755303211029598","DOIUrl":"https://doi.org/10.1177/24755303211029598","url":null,"abstract":"Introduction: Anti-TNF treatment is effective for inflammatory bowel disease (IBD), however it also has the potential to cause paradoxical psoriasis which can be challenging to manage. Discontinuation of anti-TNF agents may improve psoriatic lesions but may worsen IBD. Combining biologic therapies, though not yet commonly practiced, may be a useful approach to the treatment of both conditions. Case Presentation: We describe a case of paradoxical palmoplantar psoriasis in a 48-year-old woman with ulcerative colitis (UC). Her UC was well-managed on infliximab. Following trials of several other topical and systemic therapies for her psoriatic lesions, she ultimately received relief on combined ustekinumab and infliximab therapy without flare of her IBD. Discussion: While other publications report success using ustekinumab for paradoxical psoriasis following cessation of infliximab, this case report highlights successful treatment using a combination of ustekinumab and infliximab with no reported adverse effects at 3 months. Conclusion: Discontinuation of the anti-TNF agent and use of a single biologic that may treat both IBD and psoriasis is a treatment option. Additionally, combining biologic therapies, though not yet commonly practiced, may be a useful, albeit costly, approach to prevent potential flares of IBD that may accompany cessation of some biologics. Further studies may be beneficial to assess for long term adverse effects.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"170 - 173"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211029598","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47111350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authorial Conflicts of Interest and Sponsorship in Systematic Reviews and Meta-Analyses on Psoriasis","authors":"Michael Kee, M. Greenough, J. Anderson, Michael Weaver, M. Hartwell, M. Vassar","doi":"10.1177/24755303211020677","DOIUrl":"https://doi.org/10.1177/24755303211020677","url":null,"abstract":"Background: Because industry influence – in the form of study sponsorship and authorial conflicts of interest (COI) – can bias the results and conclusions of systematic reviews, there is a need to understand their role in systematic reviews, particularly for common conditions like psoriasis. Objectives: This study identifies conflicts of interest and industry-author relationships in systematic reviews on psoriasis treatment. Methods: Consistent with our cross-sectional design, we searched MEDLINE and Embase for systematic reviews and meta-analyses focused on psoriasis treatment. We then performed a subgroup analysis to determine further industry ties within the systemic reviews funded by industry. Results: Our study consisted of 27 systematic reviews and meta-analyses by 146 researchers. We found that 22 (81.5%) of the included systematic reviews contained at least 1 conflicted author. Six authors (of 47; 4.1%) disclosed all COI within the systematic review, 23 (of 47; 15.7%) partially disclosed COI but were also found to have undisclosed COI, and 18 (of 47; 12.3%) did not disclose any COI. Thirteen (of 22; 59.1%) contained narratives that favored the treatment group and 19 (of 22; 86.4%) reported conclusions favoring the treatment group. Importantly, 3 systematic reviews were industry-sponsored. In terms of our subgroup analysis, we found several additional industry ties within the primary studies. Conclusion: Our study calls attention to conflicts of interest, industry sponsorship, and their influence on research outcomes in systematic reviews and meta-analyses. Further, we provide examples of how specific industry ties can influence systematic reviews and recommendations for reporting.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"174 - 184"},"PeriodicalIF":0.0,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211020677","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42347262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and HealthCare Resource Utilization in Patients With Generalized Pustular Psoriasis: Real-World Evidence From a Large Claims-Based Dataset","authors":"J. Crowley, A. Golembesky, N. Kotowsky, Ran Gao, R. Bohn, E. Garry, Julia A. Pisc, W. Valdecantos, S. Feldman, A. Menter","doi":"10.1177/24755303211021786","DOIUrl":"https://doi.org/10.1177/24755303211021786","url":null,"abstract":"Background: Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease with significant unmet clinical need. Historically, GPP has not been well characterized; however, the advent of the International Classification of Diseases, 10th revision, has made it possible to more accurately characterize patients with GPP. Objective: To describe the characteristics and estimate the burden of disease in patients with GPP compared with those with plaque psoriasis. Methods: A retrospective study was conducted using a US administrative claims database, Optum® Clinformatics® Data Mart, between October 1, 2015, and March 31, 2019. Patients with at least 1 inpatient or 2 outpatient diagnosis codes for GPP (L40.1) or psoriasis vulgaris (L40.0) were included. The main outcome measures included the percentage of individuals with comorbidities, medication use, and healthcare resource utilization (HCRU), which were compared between patients with GPP and those with plaque psoriasis and a general population comparator control cohort. Results: Overall, 1,669 patients with GPP were identified at baseline; most patients were female (67.6%). Patients with GPP had more comorbidities than those with plaque psoriasis, specifically metabolic disorders: hyperlipidemia and type 2 diabetes. Medication use for patients with GPP differed from those with plaque psoriasis—patients with GPP required more frequent use of antihypertensives and antibiotics than those with plaque psoriasis. Patients with GPP also had higher HCRU than those with plaque psoriasis. Conclusion: Although this study has limitations, it shows that patients with GPP have a high burden of illness that differs from patients with plaque psoriasis.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"151 - 158"},"PeriodicalIF":0.0,"publicationDate":"2021-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211021786","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43421504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Resource Utilization and Baseline Characteristics of Patients With Generalized Pustular Psoriasis: Real-World Results From a Large US Database of Multiple Commercial Medical Insurers","authors":"J. Sobell, Ran Gao, A. Golembesky, N. Kotowsky, E. Garry, Erin Comerford, R. Bohn, W. Valdecantos, S. Feldman, C. Leonardi","doi":"10.1177/24755303211021779","DOIUrl":"https://doi.org/10.1177/24755303211021779","url":null,"abstract":"Background: Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease with high unmet clinical need. The introduction of a GPP-specific International Classification of Diseases, 10th Revision (ICD-10), code has made it possible to generate a more accurate GPP patient profile. Objectives: To describe the characteristics and compare the patient profile and burden of disease of patients with GPP with patients with plaque psoriasis. Methods: A retrospective study was conducted using a US administrative claims database, the IBM® MarketScan® Research Database. The study took place between October 1, 2015, and September 30, 2018. Patients with at least 1 inpatient or 2 outpatient L40.1 (GPP) or L40.0 (psoriasis vulgaris) diagnostic codes were included for analysis. Outcome measures included descriptions of comorbidities, medication use, and healthcare resource utilization (HCRU) among GPP, plaque psoriasis, and general population (matched to those with GPP) cohorts. Results: Patients with GPP had more baseline comorbidities than those with plaque psoriasis and the matched cohort, including psoriatic arthritis (20.6% vs 6.4% and <0.1%) and hyperlipidemia (20.4% vs 16.3% and 11.8%). Patients with GPP also had greater medication use and higher HCRU than those with plaque psoriasis and the matched cohort. Conclusion: Patients with GPP generally experience more comorbidities, with higher HCRU, than patients with plaque psoriasis. Although the large dataset permitted identification of GPP patients with longitudinal follow-up, the lack of a validation algorithm for GPP is a limitation and a potential area for future research.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"143 - 150"},"PeriodicalIF":0.0,"publicationDate":"2021-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211021779","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45192040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand","authors":"A. Armstrong, M. Lebwohl, J. Merola, Samantha Koons, R. Fried, J. Hawkes, J. Koo, R. Langley, George Martin, S. Reddy, S. Schwartzman, E. Siegel, A. V. Van Voorhees, E. Wallace, J. Weinberg, L. Howard, S. Bell","doi":"10.1177/24755303211024205","DOIUrl":"https://doi.org/10.1177/24755303211024205","url":null,"abstract":"Non-medical switching (NMS) occurs when a payer mandates that patients switch therapies, either within or across therapeutic classes, for non-medical reasons. This type of therapeutic substitution can increase the disease burden and present safety risks for patients. Often, the insurer or pharmacy benefit manager (PBM) institutes these policies due to financial incentives, which results in differential prioritization of medications on formularies. These incentives are typically not passed on to patients; rather, they are profits for the PBM or insurer. Of note, switching to a biosimilar is outside the scope of this letter. As NMS impacts therapies for psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) Medical Board strongly believes that individual treatment choices are best, and solely, determined by the prescribing healthcare provider (HCP) and their patient. Psoriasis is a chronic, systemic immune-mediated disease that requires long-term treatment. Because patients have heterogeneous presentations, therapies need to be individualized to maximize benefit and minimize risks. Each therapy has distinct characteristics including onset time, shortand long-term efficacy, effects on comorbidities, and safety profiles. In decision-making, HCPs consider patients’ presentation and medical history, as well as the MOA, efficacy, and safety of the medication before prescribing. This evidence-based approach results in adherence, greater satisfaction, and reduced burden of disease. Psoriasis in patients with an individualized regimen may remain well controlled for many years. These patients may also experience improvements in mental health and other comorbidities, or possible preventative benefit. NMS can disrupt well-controlled disease. Studies have shown that, in patients with inflammatory diseases, NMS was associated with significantly worse clinical outcomes, including increased flares, poor control, and increased health care resource utilization. In patients with psoriatic disease, NMS may negatively impact patient outcomes. For example, treatment disruptions can lead to exacerbations; the new therapy may not work as well or be tolerated as the prior treatment; or the prior treatment may become less effective when attempted later.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"126 - 127"},"PeriodicalIF":0.0,"publicationDate":"2021-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211024205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44073984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities","authors":"C. Enos, V. Ramos, R. McLean, Tin-chi Lin, Nicole Foster, Blessing Dube, A. V. Van Voorhees","doi":"10.1016/J.JID.2021.02.301","DOIUrl":"https://doi.org/10.1016/J.JID.2021.02.301","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"8 1","pages":"7 - 10"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/J.JID.2021.02.301","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41454623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary Validation of the Severity of Nail Psoriasis Score (SNAPS) for the Assessment of Nail Psoriasis in Patients With Psoriatic Arthritis","authors":"A. Antony, S. Saeed, Darren J. Hart, P. Nair, C. Cavill, E. Korendowych, N. McHugh, C. Lovell, W. Tillett","doi":"10.1177/24755303211011483","DOIUrl":"https://doi.org/10.1177/24755303211011483","url":null,"abstract":"Background: Psoriatic nail dystrophy is infrequently assessed in routine care and observational cohorts due to the lack of a feasible validated outcome measure. Objective: To assess the measurement properties of the “Severity of NAil Psoriasis Score” (SNAPS) in PsA. Methods: Nail photography was performed on prospectively recruited patients at baseline and 6 months. The modified Nail Psoriasis Severity Index (mNAPSI) and Physician Nail Visual Acuity Scale (PhNVAS) were comparator instruments for construct validity. Reliability and feasibility were assessed using intra-class correlations (ICCs) and timed scoring. Responsiveness was assessed by correlating the changes in SNAPS, mNAPSI and PhNVAS. Retrospective data from the Bath PsA database was further utilized to assess responsiveness. Results: 21 patients participated in the prospective validation at baseline. Inter- and intra-rater reliability of SNAPS were 0.94 and 0.93-0.96 (p ≤ 0.005). Mean times required to score SNAPS and mNAPSI were 59 and 136 seconds. There were strong correlations between SNAPS and mNAPSI (r = 0.95, p < 0.001) and PhNVAS (r = 0.77, p < 0.001) at baseline. There was a significant reduction in the mNAPSI and SNAPS (p < 0.005) at 6 months and a strong correlation between the change in SNAPS and mNAPSI (rho = 0.838, p < 0.001). Historical data from 57 patients commenced on Etanercept were evaluated. Mean SNAPS reduced from 3.6 to 2.0 at 3 months and 1.2 at 6 months (p < 0.05). Change in SNAPS correlated with changes in Psoriasis Area Severity Index and Dermatology Quality of Life at 3 and 6 months (r≥0.510; p ≤ 0.003). Conclusion: SNAPS is a feasible, reliable and responsive outcome instrument for psoriatic nail dystrophy.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"128 - 135"},"PeriodicalIF":0.0,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211011483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43246997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring","authors":"Anisha P. Bindagi, Bhavana Doshi, A. Pandit, Basavapudda Manjunathswamy","doi":"10.1177/24755303211011477","DOIUrl":"https://doi.org/10.1177/24755303211011477","url":null,"abstract":"Background: Nail changes in psoriasis can present as a diagnostic challenge especially in the absence of cutaneous features. They occur in approximately 40% of psoriatics and in 5% as the sole presentation. Onychoscopy as a diagnostic tool aids in better visualization of nail matrix and bed abnormalities in psoriasis patients with nail involvement. Aim: To study onychoscopic features of nails in psoriasis and correlate it clinically using nail psoriasis severity index (NAPSI). Materials and Methods: A total of 60 patients of psoriasis with nail changes were recruited in this hospital based cross-sectional study over a period of one year. Cutaneous severity was assessed using psoriasis area severity index (PASI). NAPSI was used to determine the severity of nail involvement. Nails of the patients with psoriasis were examined clinically and onychoscopically. Statistical analysis was done using the software R i386.3.6.3. Results: Pitting was the most common nail change observed on clinical and onychoscopic examination, seen in 90% and 95% patients respectively. Leuconychia, red spots in lunula, onycholysis, and splinter hemorrhages were better visualized on onychoscopy. A statistically significant higher NAPSI (P < 0.05) was obtained on onychoscopy. There was a positive co- relation between the cutaneous severity of psoriasis and the extent of nail involvement. Conclusion: Onychoscopic examination coupled with NAPSI in nail psoriasis serves as a useful guide to assess the nail involvement and provides a better insight into the subtle nail changes in psoriatics which could have been missed clinically. Limitations: Small study population, lack of age and sex matched control group.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 1","pages":"136 - 142"},"PeriodicalIF":0.0,"publicationDate":"2021-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211011477","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44149843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}